Estimated Time
1.00 hour
Release Date
Oct 14, 2022
Expiration Date
Jan 02, 2024
ACTIVITY DESCRIPTION
Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs.
What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes.
This taped satellite symposium was derived from the 58th EASD Annual Meeting on September 19, 2022.
Speakers
Juan Pablo Frias, MD
Michael A. Nauck, MD
Diabetes Division, St. Josef Hospital
Ruhr University
Bochum, Germany
Bertram Award (1993), the Werner Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) of the German Diabetes Association.
Bernhard Ludvik, MD
Associate Professor of Medicine
Head 1st Medical Department
Landstrasse Clinic
Vienna, Austria
Prof. Bernhard Ludvik, M.D., is Head of the 1st Medical Department with Diabetology, Endocrinology and Nephrology as well of the Karl Landsteiner Institute of Obesity and Metabolic Disorders at the Landstrasse Clinic, Vienna Health Organization, in Vienna, Austria. He is an Associate Professor of Medicine at the Medical University of Vienna. Bernhard Ludvik is a specialist in Internal Medicine and in Endocrinology & Diabetology.
He completed his medical education at the University of Vienna and at the Division of Endocrinology of UCSD in California. Dr. Ludvik served as vice chairman of the Division of Endocrinology at the Medical University of Vienna/General Hospital (AKH) before being appointed Head of the 1st Medical Department of the Landstrasse Clinic.
He obtained numerous awards and was president of the Austrian Diabetes Association and the Austrian Obesity Association. Currently, he is Associate Editor of Obesity Facts and has served on several editorial boards of scientific journals including Diabetologia.
He is author/coauthor of more than 180 papers in peer reviewed journals (h-index 54) and serves as reviewer for various top journals. Dr. Ludvik and his team conduct several studies in the areas of diabetes, metabolism, lipid disorders and kidney diseases in phases 2 and 3 as well as academic studies.
Accreditation and Disclosure Information
TARGET AUDIENCE
This CE activity is intended for endocrinologists, diabetologists, and endocrinology fellows who provide care for individuals with T2D in Europe, and those who attended EASD.
EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
- Identify individuals with T2D who may benefit from earlier treatment intensification to achieve optimal glucose control and overall health in accordance with current guidelines
- Integrate practical considerations, experience, and SDM techniques to help individuals with T2D achieve and maintain weight loss for optimal outcomes
- Relate the pathophysiology of GLP-1 and GIP to the incretin effect and potential benefits of agonism of multiple receptors that affect energy homeostasis and the MOA of novel therapies
- Interpret the clinical implications of the efficacy and safety data of novel dual agonists for T2D and their potential impact on the treatment paradigm
AGENDA
- Addressing Unmet Needs in T2D
- Delineating the Incretin Effect and the Roles of GLP-1 and GIP
- Benefits of Agonism of Multiple Receptors: Mechanism of Action of Unimolecular Dual Agonists
- Clinical Implications of Dual Agonis Efficacy and Safety Data
- Case Studies Addresing Comorbidities, Treatment Intensification, and Shared Decision Making
- Ask Me Anything - Q&A with Faculty
ACCREDITATION, SUPPORT AND CREDIT
The Xpeer, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists.
This course is accredited with 1 ECMEC® credit valid in 26 countries. Each medical specialist should claim only those credits that he/she actually spent in the educational activity.
The EACCME® is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credit(s)™. Information on the process to convert EACCME® credit to AMA credit can be found at: www.ama-assn.org/education/earn-credit-participation-international-activities
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., Endocrine Society and Xpeer. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
SUPPORT STATEMENT
This activity is supported by an educational grant from Lilly.
This activity is developed with our educational partners, Endocrine Society and Xpeer.
DISCLOSURES & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., Endocrine Society, and Xpeer, are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Chair/Planner/Presenter
Juan Pablo Frias, MD, FACE
Medical Director and Principal Investigator
Velocity Clinical Research
Los Angeles, CA
Juan Pablo Frias, MD, FACE, has a financial interest/relationship or affiliation in the form of:
Research Grant from Akero, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, 89bio, Eli Lilly, Intercept, Ionis, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel and Sanofi.
Advisory Board/Consultant for Akero, Altimmune, Axcella Health, Becton Dickinson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer, and Sanofi.
Speakers’ Bureau with Eli Lilly and Sanofi.
Planner/Presenter
Bernhard Ludvik, MD
Associate Professor of Medicine
Head 1st Medical Department
Landstrasse Clinic
Vienna, Austria
Bernhard Ludvik, MD, has a financial interest/relationship or affiliation in the form of:
Research Grant from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Madrigal, Novo Nordisk, and Sanofi.
Advisory Board/Consultant for Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi.
Speakers’ Bureau with Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi.
Planner/Presenter
Michael A. Nauck, MD, Dr. h.c.
Head of Clinical Research Diabetologie
St. Josef Hospital (Ruhr University)
Bochum, Germany
Michael A. Nauck, MD, has a financial interest/relationship or affiliation in the form of:
Research Grant from AstraZeneca, Berlin-Chemie, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Novo Nordisk.
Advisory Board/Consultant for Berlin-Chemie, Boehringer Ingelheim, Eli Lilly, Inventiva, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Regor Pharmaceutical, and ShouTi (Gasherbrum).
Speakers’ Bureau with AstraZeneca, Berlin-Chemie, Eli Lilly, GlaxoSmithKline, Intas Pharmaceuticals, Merck Sharp & Dohme, Novo Nordisk, Sanofi, and Sun Pharma.
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., Endocrine Society, and Xpeer, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
DISCLOSURES OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.